A Role of Cytokines in OK-432 Injection Therapy for Cystic Lymphangioma: An Approach to the Mechanism

Journal of Pediatric Surgery

Volumn 38, Issue 12, 2003, Pages 1806-1809

  Fujino, Akihiro ^b   Moriya, Yoichiro ^a   Morikawa, Yasuhide ^a   Hoshino, Ken ^a   Watanabe, Toshihiko ^a   Shimojima, Naoki ^a   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization Tochigi Medical Center   (Japan)

Author keywords

Cytotoxicity; Fibrotic change; Lymphangioma; OK 432; Transforming growth factor beta 1; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; PICIBANIL; PROTEIN P40; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ASPIRATION; CASE REPORT; CELL CULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CYST FLUID; CYSTIC LYMPHANGIOMA; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; INJECTION; MALE; MONONUCLEAR CELL; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCLEROSIS; SUPERNATANT; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0344738893     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2003.08.041     Document Type: Conference Paper

References (13)

1. Giguère CM, Bauman NM, Smith RJ: New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol 111:1066-1075, 2002
2. Ogita S, Tsuto T, Nakamura K, et al: OK-432 therapy in 64 patients with lymphangioma. J Pediatr Surg 29:784-785, 1994
3. Greinwald JH Jr, Burke DK, Sato Y, et al: Treatment of lymphangiomas in children: An update of Picibanil (OK-432) sclerotherapy. Otolaryngol Head Neck Surg 121:381-387, 1999
4. Sakano S, Shimabukuro T, Ohmoto Y, et al: Cytokine-mediated antitumor effect of OK-432 on urinary bladder tumor cells in vitro. Urol Res 25:239-245, 1997
5. Tanaka N, Gouchi A, Ohara T, et al: Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. Cancer 74:3097-3103, 1994
6. Fukui H, Reynolds CW, Lenz B, et al: Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carinomatosis. Cancer Immunol Immunother 29:1-6, 1989
7. Ogita S, Tsuno T, Nakamura K: OK-432 therapy for lymphangioma in children: Why and how does it work. J Pediatr Surg 31:477-480, 1996
8. Fujimoto T, Duda RB, Szilvasi A, et al: Streptococcal preparation OK-432 is a potent inducer of IL-12 and T helper cell 1 dominant state. J Immunol 158:5619-5626, 1997
9. Toge T, Hamamoto S, Aratani K, et al: Correlation between the presence of intracellular OK-432 and antitumor activity of peritoneal macrophages. Int J Immunopharmacol 8:599-603, 1986
10. Shamoto M, Zenke T: Electron microscopic study in the biopsied skin subcutaneously injected with OK-432 in cancer patients (author's translation). Nihon Monaikei Gakkai Kaishi 21:281-286, 1981
11. Quatresooz P, Henry F, Paquet P, et al: Deciphering the impaired cytokine cascades in chronic leg ulcers (Review). Int J Mol Med 11:411-418, 2003
12. -T-cells. Cancer Res 50:4630-4634, 1990
13. Davis MR, Banieghbal B: Guidelines for the successful treatment of lymphangioma with OK-432. Eur J Pediatr Surg 13:103-107, 2003